Roquefort Therapeutics plc (LON:ROQ)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1.650
-0.125 (-7.55%)
Aug 18, 2025, 4:35 PM BST
-7.55%
Market Cap2.60M
Revenue (ttm)n/a
Net Income (ttm)-971.80K
Shares Out157.44M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40,908
Average Volume1,563,240
Open1.526
Previous Close1.650
Day's Range1.526 - 1.650
52-Week Range1.080 - 6.780
Beta-0.43
RSI53.81
Earnings DateSep 26, 2025

About Roquefort Therapeutics

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in v... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 7
Stock Exchange London Stock Exchange
Ticker Symbol ROQ
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.